Letter to the Editor: comparison of ofatumumab and other disease-modifying therapies for relapsing multiple sclerosis: a network meta-analysis

被引：0
作者：
Parekh, Krupa [1 ]
Watkins, Claire [2 ]
机构：
[1] F Hoffmann La Roche Ltd, Basel, Switzerland
[2] Clarostat Consulting Ltd, Macclesfield, Cheshire, England
来源：
JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH | 2021年 / 10卷 / 17期
关键词：
disease-modifying therapies; multiple sclerosis; network meta-analysis; relapsing multiple sclerosis;
D O I：
10.2217/cer-2021-0123
中图分类号：
R19 [保健组织与事业（卫生事业管理）];
学科分类号：
摘要：
引用
收藏
页码：1265 / 1266
页数：2
相关论文
共 50 条
  • [21] Assessing the risk of multiple sclerosis disease-modifying therapies
    Ayrignac, Xavier
    Bilodeau, Philippe-Antoine
    Prat, Alexandre
    Girard, Marc
    Labauge, Pierre
    Le Lorier, Jacques
    Larochelle, Catherine
    Duquette, Pierre
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2019, 19 (07) : 695 - 706
  • [22] Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: a practical review and meta-analysis
    Etemadifar, Masoud
    Nouri, Hosein
    Pitzalis, Maristella
    Idda, Maria Laura
    Salari, Mehri
    Baratian, Mahshid
    Mahdavi, Sepide
    Abhari, Amir Parsa
    Sedaghat, Nahad
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2022, 93 (09) : 986 - 994
  • [23] Cancer in multiple sclerosis patients following prolonged exposure to disease-modifying therapies (DMTs): a systematic review and meta-analysis
    Giannopapas, Vasileios
    Smyrni, Vassiliki
    Kitsos, Dimitrios K.
    Stefanou, Maria Ioanna
    Theodorou, Aikaterini
    Tzartos, John S.
    Tsivgoulis, Georgios
    Giannopoulos, Sotirios
    JOURNAL OF NEUROLOGY, 2025, 272 (02)
  • [24] Comparative efficacy of therapies for relapsing multiple sclerosis: a systematic review and network meta-analysis
    Samjoo, Imtiaz A.
    Drudge, Christopher
    Walsh, Sarah
    Tiwari, Santosh
    Brennan, Roisin
    Boer, Ibolya
    Haering, Dieter A.
    Klotz, Luisa
    Adlard, Nicholas
    Banhazi, Judit
    JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2023, 12 (07)
  • [25] Emerging multiple sclerosis disease-modifying therapies
    Giacomini, Paul S.
    Darlington, Peter J.
    Bar-Or, Amit
    CURRENT OPINION IN NEUROLOGY, 2009, 22 (03) : 226 - 232
  • [26] Oral Disease-Modifying Therapies for Multiple Sclerosis
    Kim, Woojun
    Zandona, Manuella Edler
    Kim, Su-Hyun
    Kim, Ho Jin
    JOURNAL OF CLINICAL NEUROLOGY, 2015, 11 (01): : 9 - 19
  • [27] Seizure risk in multiple sclerosis patients treated with disease-modifying therapy: A systematic review and network meta-analysis
    Dang, Yew Li
    Yong, Vivien T. Y.
    Sharmin, Sifat
    Perucca, Piero
    Kalincik, Tomas
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 (06) : 657 - 667
  • [28] Current disease-modifying therapies in multiple sclerosis
    Kieseier, BC
    Hartung, HP
    SEMINARS IN NEUROLOGY, 2003, 23 (02) : 133 - 145
  • [29] Price analysis of multiple sclerosis disease-modifying therapies marketed in the United States
    Bin Sawad, Aseel
    Seoane-Vazquez, Enrique
    Rodriguez-Monguio, Rosa
    Turkistani, Fatema
    CURRENT MEDICAL RESEARCH AND OPINION, 2016, 32 (11) : 1783 - 1788
  • [30] Cost-effectiveness of injectable disease-modifying therapies for the treatment of relapsing forms of multiple sclerosis in Spain
    Carole Dembek
    Leigh Ann White
    Jayson Quach
    Andrea Szkurhan
    Nazia Rashid
    M. R. Blasco
    The European Journal of Health Economics, 2014, 15 : 353 - 362
12345